[Bacteriological evaluation of clindamycin-2-phosphate (author's transl)].
Clindamycin-2-phosphate, a newly developed injectable antibiotic, was bacteriologically evaluated in comparison with the parent compound, clindamycin. Clindamycin-2-phosphate has a rather weak antibacterial activity. However, it is metabolized into clindamycin in vivo. And this parent compound shows strong activity against both gram-positive bacteria and gram-negative cocci. In vitro studies demonstrated that clindamycin-2-phosphate and clindamycin are affected by the pH of the medium used--the antibacterial activity becomes stronger as the medium is made more alkaline--while they are little affected by the size of the inoculum. In mice with experimental infections, clindamycin-2-phosphate showed about the same therapeutical effect as clindamycin in contrast with the former's inferior in vitro activity as compared with the latter.
D000818:Animals; D002981:Clindamycin / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D004352:Drug Resistance, Microbial; D008297:Male; D051379:Mice; D009943:Organophosphorus Compounds; D013203:Staphylococcal Infections / Q000188:drug therapy; D013211:Staphylococcus aureus / Q000187:drug effects; D013290:Streptococcal Infections / Q000188:drug therapy; D013296:Streptococcus pneumoniae / Q000187:drug effects
D009943:Organophosphorus Compounds; D002981:Clindamycin